The protein and peptide therapeutics industry is undergoing a profound transformation driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and glucagon-like peptide-1 (GLP-1) treatments, leading to enhanced competition.

New monoclonal antibodies (mAbs) aiming at autoimmune, infectious, and cardiovascular disorders, fusion proteins with long half-lives, and developments in enzyme replacement treatments and cytokine engineering define drug development trends. While extended-release and easy formulations increase cost-effectiveness, adherence, and access, platform-based peptide methods stress multifunctional medicines with improved receptor selectivity and longer half-lives.

Protein and peptide treatments are becoming increasingly important as precision-targeted, physiologically strong therapy choices as the global illness burden rises, especially in oncology, metabolic diseases, and autoimmune ailments. The fast-expanding therapeutic class nowadays is GLP-1s and multi-agonist peptides because of the worldwide obesity crisis.

A mix of industry dynamics, including major price cuts, more biosimilar competition, and a change in treatment preferences toward GLP-1 receptor agonists, drives the drop in sales of insulin products, which are now used not only for diabetes control but also for treating sleep apnea, obesity, and lowering cardiovascular risk.

• Which regional megatrends, technical developments, and clinical pathways will influence the growth potential of protein and peptide therapeutics like mAbs, fusion proteins, GLP-1 analogs, peptide hormones, coagulation factors, cytokines, interleukins and therapeutic enzymes?
  
• What are the major pharmaceuticals, biosimilars, and new modalities impacting the growth of key therapeutic areas like cancer, endocrinology, infectious diseases, and immunology?
  
• How can you leverage collaboration approaches and innovation hotspots in oral peptide delivery, focused protein degradation, and multi-functional biologics?